PMH43 - COST-UTILITY ANALYSIS OF CARIPRAZINE COMPARED TO RISPERIDONE AMONG PATIENTS WITH NEGATIVE SYMPTOMS OF SCHIZOPHRENIA IN SELECTED CENTRAL AND EASTERN EUROPEAN COUNTRIES

The objective of this research is to assess the cost-effectiveness of cariprazine compared to second-generation antipsychotics in the treatment of schizophrenia for patients with negative symptoms in Hungary and Slovakia separately, and to compare the results of the analyses. A deterministic 8-health state Markov cohort model was built, to support the cost-utility analyses that were performed from a third-party payer perspective in both...